StockData

Vyome vs Soligenix

HIND and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIND and SNGX compare

Vyome is the larger company, worth 1.8 times as much as Soligenix ($10.8M against $6.1M).

Soligenix scores higher on the StockData Score (6 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHINDSNGX
Size and price
Market cap$10.8M$6.1M
Share price$1.54$0.281
Change, 1 year−68.3%−79.5%
Change, 5 years−100.0%−99.9%
Beta (5Y)1.602.38
Employees1814
StockData Score
Total score16 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S83.6×–
P/B–0.9×
Growth
Revenue growth (TTM)−67.1%–
Revenue growth, 5Y average−51.0%–
Profitability
Gross margin52.7%–
Operating margin−9190%–
Net margin−8717%–
Return on equity−194% (better)−242%
Return on invested capital−173%–
Financial health
Debt / equity–0.00
Interest coverage−285.8×–
Current ratio4.37 (better)2.77
Altman Z-score−13.57 (better)−35.09
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield39.6%–
Shareholder yield39.6% (better)0.00%
Ownership
Held by institutions2.0%4.3%
Held by insiders6.8%0.69%
Short interest, % of float0.28%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.